Zentalis Pharmaceuticals, Inc. (ZNTL)
Largest Insider Buys in Sector
ZNTL Stock Price History Chart
ZNTL Stock Performance
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant …
Insider Activity of Zentalis Pharmaceuticals, Inc.
Over the last 12 months, insiders at Zentalis Pharmaceuticals, Inc. have bought $0 and sold $495,115 worth of Zentalis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Zentalis Pharmaceuticals, Inc. have bought $45.2M and sold $22.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $51,448 was made by Blackwell Kimberly (Chief Executive Officer) on 2023‑11‑13.
List of Insider Buy and Sell Transactions, Zentalis Pharmaceuticals, Inc.
| 2024-10-04 | Sale | Principal Accounting Officer | 1,603 0.0019% | $3.18 | $5,098 | -4.15% | ||
| 2024-05-31 | Sale | President, Interim CFO | 9,597 0.0136% | $11.98 | $114,972 | -70.75% | ||
| 2024-05-09 | Sale | Chief Medical Officer | 3,356 0.0048% | $12.62 | $42,353 | -71.24% | ||
| 2024-02-12 | Sale | President | 1,173 0.0016% | $11.44 | $13,419 | -60.70% | ||
| 2024-02-12 | Sale | Chief Financial Officer | 2,573 0.0036% | $11.44 | $29,435 | -60.70% | ||
| 2024-02-02 | Sale | President | 11,552 0.0155% | $11.54 | $133,310 | -56.86% | ||
| 2024-02-02 | Sale | Chief Financial Officer | 8,669 0.0116% | $11.54 | $100,040 | -56.86% | ||
| 2024-02-02 | Sale | Chief Scientific Officer | 1,585 0.0021% | $11.54 | $18,291 | -56.86% | ||
| 2024-02-02 | Sale | Chief Legal Officer | 3,310 0.0044% | $11.54 | $38,197 | -56.86% | ||
| 2023-11-13 | Chief Executive Officer | 5,000 0.0071% | $10.29 | $51,448 | +12.91% | |||
| 2023-11-10 | director | 17,000 0.0243% | $9.88 | $167,943 | +18.22% | |||
| 2023-10-04 | Sale | Chief Scientific Officer | 6,068 0.0084% | $19.50 | $118,355 | -39.88% | ||
| 2023-10-04 | Sale | Chief Financial Officer | 5,482 0.0076% | $19.50 | $106,926 | -39.88% | ||
| 2023-10-04 | Sale | Chief Medical Officer | 10,628 0.0148% | $19.50 | $207,298 | -39.88% | ||
| 2023-09-11 | Sale | director | 5,000 0.0071% | $25.05 | $125,238 | -49.22% | ||
| 2023-06-20 | 10 percent owner | 4.76M 6.3802% | $22.66 | $107.86M | -48.63% | |||
| 2023-05-31 | Sale | President | 27,768 0.0473% | $26.27 | $729,506 | -41.32% | ||
| 2023-05-26 | Sale | Chief Scientific Officer | 80,000 0.1348% | $30.02 | $2.4M | -48.82% | ||
| 2023-02-14 | Sale | Chief Scientific Officer | 6,500 0.0109% | $19.98 | $129,873 | -3.41% | ||
| 2023-02-14 | Sale | President | 8,501 0.0143% | $19.96 | $169,706 | -3.41% |
Insider Historical Profitability
| Epperly Melissa B, | Chief Financial Officer | 451449 0.6335% | $3.00 | 3 | 18 | +21.94% |
| Matrix Capital Management Company, LP | 10 percent owner | 13959973 19.5887% | $3.00 | 1 | 0 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 3943284 5.5332% | $3.00 | 1 | 1 | +70.78% |
| SUN ANTHONY Y | President & CEO | 1175589 1.6496% | $3.00 | 1 | 30 | +70.78% |
| Bunker Kevin D. | Chief Scientific Officer | 859089 1.2055% | $3.00 | 1 | 41 | +70.78% |
Institutional Investor Ownership
| Matrix Capital Management Company, L.P. | $220.01M | 19.66 | 13.96M | 0% | +$0 | 2.04 | |
| Eventide Asset Management | $182.42M | 16.3 | 11.57M | +0.13% | +$233,972.96 | 2.95 | |
| Fidelity Investments | $167.75M | 14.99 | 10.64M | +2.97% | +$4.84M | 0.01 | |
| BlackRock | $73.22M | 6.54 | 4.65M | -0.84% | -$618,059.93 | <0.01 | |
| The Vanguard Group | $69.32M | 6.19 | 4.4M | -17.79% | -$15M | <0.01 |